GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
A phase 2 trial of GR1803 in multiple myeloma, run by Genrix (Shanghai) Biopharmaceutical Co., Ltd., active and no longer recruiting.
Overview
GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT06566547 by Genrix (Shanghai) Biopharmaceutical Co., Ltd., with 116 participants planned, started 2024-08-26 and due to reach its primary completion in 2027-05-12. Interventions recorded: GR1803 injection. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Setting
Single-Arm, Open, Multi-Center Phase II Clinical Trial of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
Phase
Phase 2
Sponsor
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Registry
Enrolled
116